Literature DB >> 2736524

Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells.

S Ozawa1, Y Sugiyama, J Mitsuhashi, M Inaba.   

Abstract

We presented a cell kill pharmacodynamic model for cell cycle phase-specific antitumor agents as well as that for cell cycle phase-nonspecific agents. The former was based upon assumptions that a cell population could be divided into a drug-sensitive population having sensitive (or specific) cell cycle phase(s) and a drug-resistant population in resistant cell cycle phases. This model revealed that cell killing action of antitumor agents with sufficient cell cycle phase specificity was time dependent. This time dependence was actually observed with cytosine arabinoside by colony-forming inhibition assays using Chinese hamster V79 cells. On the other hand, the present analysis indicated that cell killing effects of drugs lacking cell cycle phase specificity are dependent on C x T (concentration-time product). We analyzed cell kill kinetics of cisplatin and showed C x T dependence of cell killing action of the drug using human colon cancer WiDr cells. These results indicate that cell killing action of antitumor agents can be kinetically analyzed in terms of cell cycle phase specificity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2736524

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

2.  Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer.

Authors:  T Yoshida; E Araki; M Iigo; T Fujii; M Yoshino; Y Shimada; D Saito; H Tajiri; H Yamaguchi; S Yoshida
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo.

Authors:  T Tokui; N Maeda; C Kuroiwa; K Sasagawa; T Inoue; K Kawai; T Ikeda; T Komai
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

4.  Extracorporeal cisplatin removal using direct hemoperfusion under hepatic venous isolation for hepatic arterial chemotherapy: an experimental study on pharmacokinetics.

Authors:  Y Maekawa; Y Ku; Y Saitoh
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  Characterization of an established human, malignant, glioblastoma cell line (GBM) and its response to conventional drugs.

Authors:  P Perego; A Boiardi; N Carenini; M De Cesare; E Dolfini; I Magnani; S Martignone; A Silvani; C Soranzo
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176.

Authors:  Manabu Takagi; Takuya Honmura; Shuuji Watanabe; Reiko Yamaguchi; Masaki Nogawa; Ikumi Nishimura; Fumitaka Katoh; Masato Matsuda; Hiroyoshi Hidaka
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

7.  Membrane Transition Temperature Determines Cisplatin Response.

Authors:  Krishnan Raghunathan; Aarif Ahsan; Dipankar Ray; Mukesh K Nyati; Sarah L Veatch
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

8.  Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer.

Authors:  K Kunieda; T Seki; S Nakatani; M Wakabayashi; T Shiro; K Inoue; M Sougawa; R Kimura; K Harada
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

Review 9.  Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors.

Authors:  Xiaonan Zhang; Angelo de Milito; Maria Hägg Olofsson; Joachim Gullbo; Padraig D'Arcy; Stig Linder
Journal:  Int J Mol Sci       Date:  2015-11-13       Impact factor: 5.923

10.  Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.

Authors:  M Inaba; J Mitsuhashi; S Kawada; H Nakano
Journal:  Jpn J Cancer Res       Date:  1994-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.